In a 72-year-old patient with a prior history of cytotoxic chemotherapy who now presents with lymphocytosis, what is the recommended evaluation and management?

Evaluation and Management of Lymphocytosis in a 72-Year-Old with Prior Cytotoxic Chemotherapy

In a 72-year-old patient with prior cytotoxic chemotherapy presenting with lymphocytosis, you must first establish whether this represents chronic lymphocytic leukemia (CLL) by confirming ≥5000 monoclonal B lymphocytes/µL sustained for at least 3 months via flow cytometry, as this is the median age for CLL diagnosis and the most common cause of sustained lymphocytosis in this population 1.

Initial Diagnostic Workup

The evaluation must distinguish between three possibilities: (1) CLL/small lymphocytic lymphoma, (2) therapy-related myeloid neoplasm with reactive lymphocytosis, or (3) benign reactive lymphocytosis from prior chemotherapy.

Required Initial Testing 1:

• Complete blood count with differential - Document absolute lymphocyte count and assess for cytopenias
• Peripheral blood smear - Look for small, mature lymphocytes with narrow cytoplasm, dense nucleus without nucleoli, and aggregated chromatin (characteristic of CLL)
• Flow cytometry of peripheral blood - Essential to confirm B-cell clonality and immunophenotype:
  • CLL cells co-express CD5, CD19, CD20 (dim), CD23
  • Low surface immunoglobulin, CD20, and CD79b
  • Monoclonal κ or λ light chain restriction
  • Critical distinction: Mantle cell lymphoma also expresses CD5 but typically lacks CD23; if CD23 is present, perform cyclin D1 staining or FISH for t(11;14)

History-Specific Elements 2:

Given the prior cytotoxic chemotherapy exposure, document:

• Specific chemotherapy agents received (fludarabine, alkylating agents, anthracyclines - cumulative doses)
• Timing since last chemotherapy (therapy-related myeloid neoplasms typically occur 2-10 years post-exposure)
• Nutritional status and weight changes
• Constitutional symptoms: fever, night sweats, significant weight loss, fatigue
• Infection history (recurrent or severe infections suggest immunodeficiency)

Physical Examination Focus 1:

• Careful palpation of all lymph node areas - document size and number of enlarged nodes
• Spleen and liver size - measure in centimeters below costal margin
• Skin examination - assess for leukemia cutis (erythematous plaques would suggest acute leukemia)

Diagnostic Algorithm

If Flow Cytometry Confirms CLL Phenotype:

Pre-treatment evaluation required 1, 3:

1. Serum chemistry panel:

   • LDH (elevated suggests higher tumor burden)
   • Bilirubin
   • Serum immunoglobulin levels (hypogammaglobulinemia common)
   • Direct antiglobulin test (DAT) - screen for autoimmune hemolytic anemia

2. Infectious disease screening (mandatory before any treatment):

   • Hepatitis B and C serology
   • CMV serology
   • HIV testing

3. FISH analysis for cytogenetic abnormalities 1, 3:

   • Del(17p) and TP53 mutation status - absolutely required as this dictates treatment choice
   • Del(11q) - also has therapeutic implications
   • Perform before initiating any therapy

4. IGHV mutational status 3 - influences prognosis and treatment selection

5. Bone marrow biopsy 1:

   • Not required for diagnosis
   • Strongly recommended before myelosuppressive therapy given prior chemotherapy exposure
   • Essential for evaluating unclear cytopenias (to distinguish CLL infiltration from therapy-related marrow damage)

Clinical Staging 1:

Apply Binet staging (European standard):

• Stage A: <3 lymphoid areas involved, no anemia/thrombocytopenia
• Stage B: ≥3 lymphoid areas involved, no anemia/thrombocytopenia
• Stage C: Anemia (Hb <10 g/dL) and/or thrombocytopenia (platelets <100,000/µL)

Management Decisions

If Asymptomatic Early-Stage CLL (Binet A/B):

Watch and wait - No treatment indicated 1, 3. Monitor with:

• Clinical examination every 3-6 months
• CBC every 3-6 months
• Pneumococcal and seasonal influenza vaccination 3

If Treatment-Requiring CLL (Binet C or symptomatic):

Treatment selection is determined by three factors 4, 3:

1. TP53 mutation/del(17p) status:

   • If present: BTK inhibitors (ibrutinib) or venetoclax-based regimens - avoid chemoimmunotherapy 4, 3
   • If absent: Proceed to fitness assessment

2. Fitness assessment 4:

   • Fit patients (physically active, no major comorbidities, normal renal function):

     • Ibrutinib 3
     • Venetoclax plus obinutuzumab (alternative) 3
     • Avoid FCR given age 72 and prior chemotherapy exposure

   • Vulnerable patients (significant comorbidities, reduced function):

     • Chlorambucil plus obinutuzumab 4
     • Dose-reduced bendamustine-rituximab 4
     • BTK inhibitors remain option 4

3. IGHV mutational status 3:

   • Unmutated IGHV: Prefer BTK inhibitors
   • Mutated IGHV: Time-limited therapies (venetoclax combinations) may be preferred

If Lymphocytosis Does NOT Meet CLL Criteria:

Consider therapy-related myeloid neoplasm if:

• Blasts present on peripheral smear
• Cytopenias in other cell lines
• Action: Bone marrow biopsy with cytogenetics mandatory 2

Consider benign reactive lymphocytosis if:

• Polyclonal by flow cytometry
• Lymphocyte count <5000/µL or transient
• Action: Monitor with repeat CBC in 3 months; no specific treatment needed 2

Critical Pitfalls to Avoid

1. Do not assume lymphocytosis is benign in a 72-year-old - CLL median age is exactly 72 years 1

2. Do not skip flow cytometry - absolute requirement to distinguish monoclonal from reactive lymphocytosis 1

3. Do not initiate treatment without TP53/del(17p) testing - these patients require different therapy and have poor outcomes with standard chemoimmunotherapy 4, 3

4. Do not use FCR in this patient - age 72 with prior chemotherapy exposure makes FCR-related toxicity unacceptably high 4

5. Do not perform CT scans routinely - clinical staging should not be based on imaging outside clinical trials 1

6. Do not treat early-stage asymptomatic CLL - no survival benefit demonstrated 1, 3

7. Given prior chemotherapy exposure, maintain high suspicion for therapy-related myeloid neoplasm - if any blasts or unexplained cytopenias, proceed directly to bone marrow evaluation 2